Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 196

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 196
---
azar, a director nominee. The loans pursuant to the 2025 Loan Agreements bear interest at a rate of 8% per annum until
maturity. Pursuant to the terms of the 2025 Loan Agreements, we also agreed to pay the lenders an additional risk premium equal to
50% of their respective loan amount. The loans under the 2025 Loan Agreements mature upon the earlier of August 31, 2025 or the date of
consummation of a Qualified IPO (as such term is defined in the 2025 Loan Agreements). Furthermore, upon the occurrence of a Qualifying IPO, the Bridge Loan lenders, shall be granted
warrants to purchase such number of Ordinary Shares equal to two times their respective loan amount in addition to a risk premium
based on a price per share equal to 75% of the lowest price per share of the Ordinary Shares during the first five
trading days following the consummation of such Qualifying IPO.

Agreements and Arrangements With, and Compensation of, Directors and Executive Officers

All
of our executive officers have employment or consultancy agreements with us which contain customary provisions and representations, including confidentiality, non-competition, non-solicitation and inventions assignment
undertakings by the executive officers. None of our
employment or service provider agreements contain any terms providing for severance benefits.
Under current applicable Israeli employment laws, we may not be able to enforce (either in
whole or in part) covenants not to compete and therefore may be unable to prevent our competitors
from benefiting from the expertise of some of our former employees. See “Management—Compensation
of Executive Officers and Directors”. In addition, certain of our other executive officers
have service provider agreements with us pursuant to which they are engaged by us as independent
contractors. These service provider agreements prohibit such executive officers from engaging
in activities that would present a conflict of interest to us or would involve providing
services to our competitors. See “Management— Engagement Agreements with Executive
Officers” for additional information.

Investors’ Rights Agreement

On
February 5, 2016, we entered into an investors’ rights agreement, or
the IRA, with several of our shareholders, who hold in the aggregate a total of 2,365,980
Ordinary Shares. Pursuant to the IRA, the shareholders have a right to require that we register
such 2,365,980 Ordinary Shares under the Securities Act under specific circumstances and